IMP3 Expression External Validation As Independent Prognostic Marker For Metastatic Progression & Death For Clear Cell Renal Cell Carcinoma Patients

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 07 Jun 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - Hoffman and colleagues examined 716 specimens of sporadic clear cell renal cell carcinoma (ccRCC) for presence of IMP3 expression. 30% of tumors stained positive for this insulin-like growth factor-II mRNA binding protein.

Positive IMP3 status correlated to advanced stage, grade, and adverse pathologic features. Remarkably, a multivariate analysis that controlled for other unfavorable characteristics still showed that IMP3 expression imparted a 42% higher chance of dying from RCC.

One can envision that IMP3 and similar prognostic markers used in the context of a percutaneous 18-gauge biopsy, will someday guide management of small renal masses.

Presented by Nathan E Hoffmann, MD, Yuri Sheinin, MD, Christine M Lohse, MD, Alexander S Parker, MD, Bradley C Leibovich, MD, Zhong Jiang, MD, Eugene D Kwon, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Alexander Kutikov, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations